
Keywords: atrial fibrillation; edoxaban; net clinical benefit; oral anticoagulation; warfarinAF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 65 to 74 or ≥75 years, diabetes, stroke or transient ischemic attack, vascular disease, s